NCT04240808View on ClinicalTrials.gov

Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

March 24, 2023

Study Completion Date

October 23, 2023

Conditions
Non Hodgkin Lymphoma
Interventions
BIOLOGICAL

UCD19 CAR T Cells

Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector \[LV\] Transduced Autologous Peripheral Blood Lymphocytes)

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT04240808 - Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | Biotech Hunter | Biotech Hunter